Subject to regulatory approvals, Pfizer aims to deliver six innovative vaccines by 2025

For over a decade, Pfizer has worked with focus and rigor to build the capabilities that have allowed us to quadruple the number of vaccine programs in the clinic, and most recently, to quickly mobilize to develop a COVID-19 vaccine candidate in collaboration with BioNTech SE to help combat the COVID-19 pandemic. In 2020, Pfizer initiated five new global Phase 3 trials across nine programs in active clinical development.

Candidates for the potential “six by 2025” are vaccines to help prevent COVID-19, pneumococcal disease in adults and pediatric populations, C. difficile, meningococcal disease, respiratory syncytial virus and Lyme disease.
^{​​​​​​​}

"We are incredibly proud of the momentum we are building in the face of a uniquely challenging year,” said Nanette Cocero, President, Pfizer Vaccines. “What drives us the most are those millions of people across the globe who are depending on us to make ‘six by 2025’ a reality.”​​​​​​​

​​​​​​​The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheet at  www.cvdvaccine.com.